• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Huntingdon Life Sciences, Harlan Laboratories to rebrand

Huntingdon Life Sciences, Harlan Laboratories to rebrand

February 26, 2015
CenterWatch Staff

Huntingdon Life Sciences (HLS) and Harlan Laboratories will formally merge under one brand to reflect a new integrated management structure and broader product and service offerings of the combined organizations.

Two core business units of research model and services (RMS) and contract research services (CRS) have been established from existing capabilities across Harlan and HLS, as well as subsidiaries of both companies. The RMS business unit provides research models, lab animal diets and bedding and support services from 30 sites worldwide. The CRS business unit offers drug development and environmental sciences services, including safety assessment, analytical, metabolism, CMC and regulatory consultancy from nine facilities in Europe, the U.S. and the Middle East.

Brian Cass, CEO, said, “The decision to rebrand the two companies as one entity is the natural progression of a sustained integration process that was put in place last year. It is a symbol of the fact that as one integrated company we are now able to further diversify the range of products and services we can provide to the market, further supporting existing relationships whilst growing our business globally with new customers. It’s a hugely exciting time for our company, with our customer-led focus and flexibility in approach, our goal is to establish our new company as the number one development partner for customer service and scientific expertise.”

The combined company has 3,500 staff and sales approaching $500 million. As a result of the integration, the company is one of the largest providers of research services to the crop protection and chemical industries, suppliers of research models and services and providers of preclinical pharmaceutical development.

The formal rebrand completion and implementation will be later this year.

HLS is a privately held global provider of essential non-clinical contract research services to the pharmaceutical, crop protection and chemical industries. Harlan Laboratories is a privately held provider of non-clinical contract research, research models and services, animal diets and products, as well as services to the pharma, biotech, medical device, crop protection and chemical industries, universities, government and other research organizations.

Check out the Monday, March 02, CWWeekly to read Ron Rosenberg's story for more information.

Upcoming Events

  • 11Feb

    Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

  • 23Mar

    Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Resources-360x240.png

    Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

  • FocusinRed-360x240.png

    Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

  • VaccinewithNeedle-360x240.png

    2021 Vaccine Industry Will Continue to be Dominated by COVID-19 Trials, Experts Say

  • Dominate-360x240.png

    COVID-19, Oncology, CNS and Infectious Disease Trials Will Dominate in 2021, Survey Predicts

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing